Cancer Family
Epithelial Neoplasm
CI-CAN-00000016Explore in graph →
Non-malignant7,525 active trials118 approved drugs1,152 evidence items
- NCIt
- C3709
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000016Explore in graph →
Clinical trials
26,878 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05104281 | Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 60 | Qingdao Central HospitalOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT00526396 | STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study(STAD-1) | unknown | Phase 3 | 160 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 |
| clinicaltrials |
| NCT01405586 | MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer(MILES-3) | unknown | Phase 3 | 299 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT01656551 | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer(MILES-4) | unknown | Phase 3 | 232 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT02633189 | Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer(BEVERLY) | unknown | Phase 3 | 200 | National Cancer Institute, NaplesOTHER | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05408221 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 576 | Shandong New Time Pharmaceutical Co., LTDINDUSTRY | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05111197 | Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy(TRAILOCLORI01) | unknown | Phase 3 | 112 | Institut Cancerologie de l'OuestOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04387695 | SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | unknown | Phase 3 | 54 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05718167 | TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer. | unknown | Phase 3 | 570 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05720026 | Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer | unknown | Phase 3 | 560 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02025036 | Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer(CRTCOESC) | unknown | Phase 3 | 249 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02125396 | Adjuvant Radiotherapy Comparing TACE for Curative HCC(ARTC-HCC) | unknown | Phase 3 | 150 | Guangxi Medical UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT03849768 | A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients | unknown | Phase 3 | 429 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05280444 | Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 216 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05344924 | TACE Combined With Penpulimab and Anlotinib for Advanced HCC | unknown | Phase 2 / Phase 3 | 109 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05661240 | Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment | unknown | Phase 2 / Phase 3 | 348 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05648071 | First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial(SPBPDC) | unknown | Phase 3 | 60 | Qianfoshan HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05622890 | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer | unknown | Phase 3 | 35 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT01855451 | Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma(HPVOropharynx) | unknown | Phase 3 | 189 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Nov 18, 2022 | clinicaltrials |
| NCT05042375 | A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | unknown | Phase 3 | 450 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05605613 | PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial | unknown | Phase 2 / Phase 3 | 150 | Xuhua DuanOTHER | 1 | Nov 9, 2022 | clinicaltrials |
| NCT03837808 | Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma | unknown | Phase 3 | 384 | Sun Yat-sen UniversityOTHER | 1 | Nov 7, 2022 | clinicaltrials |
| NCT05580341 | Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9 | unknown | Phase 3 | 1,200 | Shanghai Zerun Biotechnology Co.,LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT02773485 | Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma | unknown | Phase 3 | 155 | Tata Memorial HospitalOTHER_GOV | 1 | Oct 21, 2022 | clinicaltrials |
| NCT04942275 | Lung Perfusion PET / CT Using Ga68-MAA for Preservation of Lung Function During Stereotactic Pulmonary Radiation Therapy(PEGASUS) | unknown | Phase 2 / Phase 3 | 60 | University Hospital, BrestOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT05519956 | Elective Level Ib Irradiation in Nasopharyngeal Carcinoma Patients Based on the International Guidelines | unknown | Phase 3 | 398 | Fujian Cancer HospitalOTHER_GOV | 0 | Sep 19, 2022 | clinicaltrials |
| NCT05544253 | Safety and Efficacy of Mitomycin C-based HIPEC After srHCC and PM of HCC | unknown | Phase 2 / Phase 3 | 68 | West China HospitalOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT04898374 | Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 120 | Kuwait Cancer Control CenterOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05043402 | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 400 | OncXerna Theraputics, Inc.INDUSTRY | 0 | Aug 15, 2022 | clinicaltrials |
| NCT04484415 | Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)(APRICITY) | unknown | Phase 3 | 402 | Asieris MediTech (Hong Kong) Co., Ltd.INDUSTRY | 1 | Aug 12, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT05472896 | TACE With Dicycloplatin(TP21) in Unresectable HCC | unknown | Phase 3 | 332 | Gao-jun TengOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05203562 | Letrozole as a Prophylaxis From GTN for Complete Mole Patients | unknown | Phase 2 / Phase 3 | 200 | Zagazig UniversityOTHER_GOV | 1 | Jul 12, 2022 | clinicaltrials |
| NCT03707509 | Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 3 | 263 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05213312 | Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC | unknown | Phase 2 / Phase 3 | 90 | Shanghai Zhongshan HospitalOTHER | 1 | Jun 15, 2022 | clinicaltrials |
| NCT03623737 | Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC | unknown | Phase 2 / Phase 3 | 248 | National Taiwan University HospitalOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT02639650 | Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor | unknown | Phase 3 | 214 | Weiguo LvOTHER | 1 | Jun 3, 2022 | clinicaltrials |
| NCT04756713 | Second Uterine Evacuation for Low-risk Gestational Trophoblastic Neoplasia(ReCure) | unknown | Phase 3 | 150 | Brigham and Women's HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05231382 | Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma | unknown | Phase 3 | 426 | Sun Yat-sen UniversityOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT05220020 | TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer | unknown | Phase 3 | 299 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2022 | clinicaltrials |
| NCT05374252 | Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients | unknown | Phase 3 | 102 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT02794337 | TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer(TACE-SBRT) | unknown | Phase 2 / Phase 3 | 67 | Tata Memorial HospitalOTHER_GOV | 1 | Apr 27, 2022 | clinicaltrials |
| NCT05346861 | Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab | unknown | Phase 3 | 240 | Fudan UniversityOTHER | 1 | Apr 26, 2022 | clinicaltrials |
| NCT05346952 | A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). | unknown | Phase 3 | 390 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2022 | clinicaltrials |
| NCT04229615 | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | unknown | Phase 3 | 690 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03711305 | Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) | unknown | Phase 3 | 462 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 18, 2022 | clinicaltrials |
| NCT05322187 | Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy(sPLENTY-pc) | unknown | Phase 2 / Phase 3 | 15 | RenJi HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT04325763 | A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) | unknown | Phase 3 | 315 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03086993 | Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 295 | Delcath Systems Inc.INDUSTRY | 1 | Mar 24, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Mar 29, 2023source: clinicaltrials